These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19025421)

  • 1. Modulation of clopidogrel pharmacodynamic response.
    Goodsaid FM
    Pharmacotherapy; 2008 Dec; 28(12):1423-4. PubMed ID: 19025421
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
    Farid NA; Small DS; Payne CD; Jakubowski JA; Brandt JT; Li YG; Ernest CS; Salazar DE; Konkoy CS; Winters KJ
    Pharmacotherapy; 2008 Dec; 28(12):1483-94. PubMed ID: 19025429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel.
    Achar S
    Postgrad Med; 2011 Jan; 123(1):73-9. PubMed ID: 21293086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
    Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ
    J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of the environment on diseases and drugs.
    Bonello L; Frère C; Paganelli F; Laine M
    J Am Coll Cardiol; 2013 Aug; 62(6):513-5. PubMed ID: 23747765
    [No Abstract]   [Full Text] [Related]  

  • 6. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
    Erlinge D; Gurbel PA; James S; Lindahl TL; Svensson P; Ten Berg JM; Foley DP; Wagner H; Brown PB; Luo J; Zhou C; Moser BA; Jakubowski JA; Small DS; Winters KJ; Angiolillo DJ
    J Am Coll Cardiol; 2013 Aug; 62(7):577-83. PubMed ID: 23747759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
    Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
    Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
    J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of the atorvastatin-clopidogrel drug-drug interaction.
    Lau WC; Carville DG; Bates ER
    Circulation; 2004 Aug; 110(6):e66-7; author reply e66-7. PubMed ID: 15302813
    [No Abstract]   [Full Text] [Related]  

  • 10. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study.
    Angiolillo DJ; Saucedo JF; Deraad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Effron MB;
    J Am Coll Cardiol; 2010 Sep; 56(13):1017-23. PubMed ID: 20846599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
    Small DS; Farid NA; Payne CD; Weerakkody GJ; Li YG; Brandt JT; Salazar DE; Winters KJ
    J Clin Pharmacol; 2008 Apr; 48(4):475-84. PubMed ID: 18303127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin and clopidogrel.
    Damkier P
    Circulation; 2003 Sep; 108(13):e96; author reply e96. PubMed ID: 14517157
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolic differences of current thienopyridine antiplatelet agents.
    Fareed J; Jeske W; Thethi I
    Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):307-17. PubMed ID: 23289968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential statin-clopidogrel interaction requires more study.
    Williams D; Ford I; Hawksworth G
    Circulation; 2004 Aug; 110(6):e68; author reply e68. PubMed ID: 15302814
    [No Abstract]   [Full Text] [Related]  

  • 15. [Platelet inhibition with prasugrel].
    Gassanov N; Caglayan E; Nia AM; Erdmann E; Er F
    Dtsch Med Wochenschr; 2010 Aug; 135(31-32):1542-6. PubMed ID: 20665417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
    Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study.
    Serebruany VL; Midei MG; Malinin AI; Oshrine BR; Lowry DR; Sane DC; Tanguay JF; Steinhubl SR; Berger PB; O'Connor CM; Hennekens CH
    Arch Intern Med; 2004 Oct; 164(18):2051-7. PubMed ID: 15477442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV; Papathanasiou AI; Elisaf M; Goudevenos JA; Tselepis AD
    Platelets; 2005 Aug; 16(5):287-92. PubMed ID: 16011979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
    Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
    Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.